{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T08:42:03Z","timestamp":1761986523676},"reference-count":23,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CVP"],"published-print":{"date-parts":[[2019,1,9]]},"abstract":"<jats:sec>\n<jats:title \/>\n<jats:p>Clopidogrel remains a widely used antiplatelet agent for patients with established or high risk\nof atherothrombotic disease, particularly those treated with coronary, carotid or peripheral endovascular\nstenting. Clopidogrel hypersensitivity is an uncommon but well established adverse drug reaction presenting\na challenge for patient management. The clinical presentation ranges from focal or diffuse cutaneous\nmanifestations in most patients to angioedema in some and a systemic immune response in rare\ncases. The treatment options include drug discontinuation with or without desensitization therapy,\nswitching to alternate ADP receptor antagonists or administration of oral steroids while continuing\nclopidogrel in patients at high risk of adverse events with clopidogrel discontinuation. In this review the\nauthor describes the phenomenon of clopidogrel hypersensitivity, various treatment strategies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389200219666180820114435","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T01:01:57Z","timestamp":1535331717000},"page":"119-122","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Managing Clopidogrel Hypersensitivity without Interrupting Therapy: The Toronto Approach"],"prefix":"10.2174","volume":"17","author":[{"given":"Asim N.","family":"Cheema","sequence":"first","affiliation":[{"name":"Division of Cardiology, Terrence Donnelly Heart Center, St. Michael\u2019s Hospital, Toronto, ON M5B 1W8, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"Yusuf S.","year":"2001","unstructured":"Yusuf S, Zhao F, Mehta SR. N Engl J Med, Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.,, 2001, 345,, 494-502,","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa050522","volume":"352","author":"Sabatine M.S.","year":"2005","unstructured":"Sabatine MS, Cannon CP, Gibson CM. N Engl J Med, Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.,, 2005, 352,, 1179-1189,","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"","year":"1996","unstructured":". Lancet, CAPRIE steering committee. A randomised, blinded, trial of Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE).,, 1996, 348,, 1329-1339,","journal-title":"Lancet"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.avsg.2012.05.001","volume":"27","author":"Allemang M.T.","year":"2013","unstructured":"Allemang MT, Rajani RR, Nelson PR, Hingorani A, Kashyap VS. Ann Vasc Surg, Prescribing patterns of antiplatelet agents are highly variable after lower extremity endovascular procedures.,, 2013, 27,, 62-67,","journal-title":"Ann Vasc Surg"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"303","DOI":"10.2310\/6670.2008.00081","volume":"16","author":"Gortler D.","year":"2008","unstructured":"Gortler D, Schlosser FJ, Muhs BE, Nelson MA, Dardik A. Vascular, Periprocedural drug therapy in carotid artery stenting: The need for more evidence.,, 2008, 16,, 303-309,","journal-title":"Vascular"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1161\/CIRCULATIONAHA.106.180944","volume":"115","author":"Grines C.L.","year":"2007","unstructured":"Grines CL, Bonow RO, Casey DE. Circulation, Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American heart association, American college of cardiology, society for cardiovascular angiography and interventions, American college of surgeons, and American dental association, with representation from the American college of physicians.,, 2007, 115,, 813-818,","journal-title":"Circulation"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/j.jacc.2011.06.040","volume":"58","author":"Cheema A.N.","year":"2011","unstructured":"Cheema AN, Mohammad A, Hong T. J Am Coll Cardiol, Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation.,, 2011, 58,, 1445-1454,","journal-title":"J Am Coll Cardiol"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1136\/heartjnl-2015-308840","volume":"102","author":"Chin C.T.","year":"2016","unstructured":"Chin CT, Boden WE, Roe MT. Heart, Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.,, 2016, 102,, 1221-1229,","journal-title":"Heart"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.ijcard.2016.11.240","volume":"228","author":"Bagai A.","year":"2017","unstructured":"Bagai A, Wang TY, Goodman SG. Int J Cardiol, Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian observational anti-platelet study.,, 2017, 228,, 459-464,","journal-title":"Int J Cardiol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ijcard.2017.02.096","volume":"235","author":"Sheikh Rezaei S.","year":"2017","unstructured":"Sheikh Rezaei S, Geroldinger A, Heinze G, Reichardt B, Wolzt M. Int J Cardiol, Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.,, 2017, 235,, 61-66,","journal-title":"Int J Cardiol"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1253\/circj.CJ-13-0795","volume":"78","author":"Alexopoulos D.","year":"2014","unstructured":"Alexopoulos D, Xanthopoulou I, Deftereos S. Circ J, Contraindications\/special warnings and precautions for use of contemporary oral antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.,, 2014, 78,, 180-187,","journal-title":"Circ J"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000447396","volume":"136","author":"Beigel R.","year":"2017","unstructured":"Beigel R, Iakobishvili Z, Shlomo N. Cardiology, Real-world use of novel p2y12 inhibitors in patients with acute myocardial infarction: A treatment paradox.,, 2017, 136,, 21-28,","journal-title":"Cardiology"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"Wallentin L.","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A. N Engl J Med, Ticagrelor versus clopidogrel in patients with acute coronary syndromes.,, 2009, 361,, 1045-1057,","journal-title":"N Engl J Med"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"Wiviott S.D.","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH. N Engl J Med, Prasugrel versus clopidogrel in patients with acute coronary syndromes.,, 2007, 357,, 2001-2015,","journal-title":"N Engl J Med"},{"key":"ref=15","first-page":"9","author":"Fosbol E.L.","year":"2016","unstructured":"Fosbol EL, Ju C, Anstrom KJ. Circ Cardiovasc Interv, Early cessation of adenosine diphosphate receptor inhibitors among acute myocardial infarction patients treated with percutaneous coronary intervention: insights from the translate-ACS study (Treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome).,, 2016, 357,, 9-,","journal-title":"Circ Cardiovasc Interv"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ahj.2016.10.006","volume":"183","author":"Zettler M.E.","year":"2017","unstructured":"Zettler ME, Peterson ED, McCoy LA. Am Heart J, Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the treatment with adenosine diphosphate receptor inhibitors: Longitudinal assessment of treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) observational study.,, 2017, 183,, 62-68,","journal-title":"Am Heart J"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1161\/CIRCINTERVENTIONS.108.832964.108.832964","volume":"2","author":"Lokhandwala J.O.","year":"2009","unstructured":"Lokhandwala JO, Best PJ, Butterfield JH. Circ Cardiovasc Interv, Frequency of allergic or hematologic adverse reactions to ticlopidine among patients with allergic or hematologic adverse reactions to clopidogrel.,, 2009, 2,, 348-351,","journal-title":"Circ Cardiovasc Interv"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.281.9.806","volume":"281","author":"Steinhubl S.R.","year":"1999","unstructured":"Steinhubl SR, Tan WA, Foody JM, Topol EJ. JAMA, Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb\/IIIa Inhibitor for Stenting.,, 1999, 281,, 806-810,","journal-title":"JAMA"},{"key":"ref=19","first-page":"341","volume":"18","author":"Walker N.E.","year":"2006","unstructured":"Walker NE, Fasano MB, Horwitz PA. J Invasive Cardiol, Desensitization for the management of clopidogrel hypersensitivity: Initial clinical experience.,, 2006, 18,, 341-344,","journal-title":"J Invasive Cardiol"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/j.jacc.2007.08.016","volume":"50","author":"von Tiehl K.F.","year":"2007","unstructured":"von Tiehl KF, Price MJ, Valencia R. J Am Coll Cardiol, Clopidogrel desensitization after drug-eluting stent placement.,, 2007, 50,, 2039-2043,","journal-title":"J Am Coll Cardiol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/ccd.20919","volume":"69","author":"Camara M.G.","year":"2007","unstructured":"Camara MG, Almeda FQ. Catheter Cardiovasc Interv, Clopidogrel (Plavix) desensitization protocol.,, 2007, 69,, 154-,","journal-title":"Catheter Cardiovasc Interv"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1345\/aph.1M379","volume":"44","author":"Fajt M.","year":"2010","unstructured":"Fajt M, Petrov A. Ann Pharmacother, Clopidogrel hypersensitivity: A novel multi-day outpatient oral desensitization regimen.,, 2010, 44,, 11-18,","journal-title":"Ann Pharmacother"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1445-5994.2010.02266.x","volume":"40","author":"Fernando S.L.","year":"2010","unstructured":"Fernando SL, Assaad NN. Intern Med J, Rapid and sequential desensitization to both aspirin and clopidogrel.,, 2010, 40,, 596-599,","journal-title":"Intern Med J"}],"container-title":["Current Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/164762","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T02:58:12Z","timestamp":1566269892000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/164762\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,9]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200219666180820114435","relation":{},"ISSN":["1570-1611"],"issn-type":[{"value":"1570-1611","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}